Management of Hypertriglyceridemia in Diabetic Patients

Primary Treatment Approach

The American Diabetes Association recommends optimizing glycemic control as the first priority, followed by therapeutic lifestyle changes, including weight loss, increased physical activity, reduced alcohol consumption, and dietary modifications, for diabetic patients with hypertriglyceridemia 1, 2, 3
For triglyceride levels 200-400 mg/dL, clinical judgment should determine the need for medication, while levels >400 mg/dL warrant strong consideration for pharmacological treatment to minimize pancreatitis risk 2, 3, 4

Fibric acid derivatives, such as fenofibrate, are the most potent triglyceride-lowering agents, reducing levels by up to 50%, and are specifically indicated for severe hypertriglyceridemia in diabetic patients 2, 3
Fenofibrate increases HDL cholesterol levels without affecting glycemic control, and may improve glycemic control and reduce insulin resistance 5, 6

Patients with marked hypertriglyceridemia (≥200 mg/dL) and low HDL-C (≤40 mg/dL) showed significant reduction in cardiovascular disease events with fenofibrate 3
Fenofibrate should be used with caution in patients with renal impairment, and is contraindicated in severe renal impairment 7

For diabetic patients with both elevated LDL and triglycerides, improved glycemic control plus high-dose statin is the first choice, followed by improved glycemic control plus statin plus fenofibrate (with caution due to myositis risk) 1, 2

Severe hypertriglyceridemia (≥1,000 mg/dL) requires severe dietary fat restriction (<10% of calories) in addition to pharmacological therapy to reduce pancreatitis risk 5, 6
Combination therapy with fenofibrate and statins should be used with caution due to increased risk of myositis, though the risk appears lower with fenofibrate than with gemfibrozil 2, 3

The American Academy of Family Physicians recommends weight loss for overweight/obese patients, reduced intake of simple carbohydrates and alcohol, and increased physical activity as initial management for all patients with hypertriglyceridemia 8
For patients with moderate hypertriglyceridemia (200-499 mg/dL), fenofibrate may be considered when therapeutic lifestyle changes have been unsuccessful and the patient has additional cardiovascular risk factors or low HDL-C levels 8
The American College of Cardiology recommends evaluating renal function before starting fenofibrate, within 3 months after initiation, and every 6 months thereafter, and limiting the dose to 54 mg/day for patients with eGFR between 30-59 mL/min/1.73 m² 9
For diabetic patients with marked hypertriglyceridemia (≥200 mg/dL) and low HDL-C (≤40 mg/dL), fenofibrate may be considered to reduce cardiovascular disease events 8

The American College of Cardiology recommends monitoring lipid levels 4-12 weeks after initiation and every 3-12 months thereafter, and adjusting the dosage if necessary following repeat lipid determinations at 4-8 week intervals 9
The American Journal of Kidney Diseases recommends avoiding fenofibrate if eGFR <30 mL/min/1.73 m² 10
When combining fenofibrate with statins, the American College of Cardiology recommends using caution due to potential increased risk of myositis 9